Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells
By C. Yee, John A. Thompson, David R. Byrd, Stanley R. Riddell, P. Roche, E. Celis, Philip D. Greenberg. Proceedings of the National Academy of Sciences of the United States of America, 2002
1,286 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/7eb821f99d6b10f15f0cd5fcb7ed46f56840f3bd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Immunology
In Oncology
Citations in the corpus
- Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. (2013, neutral): “3 9 64/F L (0) IFN (3); Sor + IL2 (14) Lu”
- Mechanisms of immune evasion by tumors. (2006, background): “Heterogeneity of TAA expression and attempts to correlate TAA loss are well documented in murine tumor models with transplantation of immunogenic tumors or after vaccination (Lethe et al., 1992; Urban et al., 1986; Uyttenhove et al., 1983;Ward et al., 1989; Wortzel et al., 1983; Yee et al., 2002).”
- Cancer immunotherapy (2012, background): “It is neither yet clear thatmassive lymphodepletion is actually required for optimal efficacy of adoptively transferred T cells, nor that high-dose IL-2 is absolutely required.”
- Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010, background): “Although initially focused on CD8+ CTL responses (Yee et al., 2002), recent preclinical and clinical studies have redirected attention to CD4+ T cells, which are thought to provide the necessary help to the effector CD8+ CTL compartment (Hunder et al., 2008).”
- Cancer immunotherapy via dendritic cells (2012, neutral): “This goal is encouraged by clinical studies showing that the infusion of autologous tumour-specific CD8 + T cells can eventually lead to the rejection of large metastatic tumours in patient”
- Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. (2005, methodology): “Currently, the only criterion applied to selecting cells for adoptive transfer to patients with solid tumors is the ability of antitumor T cells to release IFN-γ and kill tumor cells upon coculture (2, 10).”
- Cytokines in Cancer Immunotherapy (2011, background): “In addition to the use of ex vivo cytokines in the generation of T cells, the administration of low-dose IL-2 to the patient following T cell infusions has been found to enhance the in vivo survival of the adoptively transferred cells, which is highly correlated with clinical outcome [203].”